Multiplex PCR Pneumonia Panel in Critically Ill Patients Did Not Modify Mortality: A Cohort Study
Open Access
- 28 February 2025
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 14 (3) , 245
Abstract
In critically ill patients, identification of the pathogen may allow for the timely adjustment of antibiotics and improved outcomes. Background/Objectives: The aim of the study was to assess whether performing a multiplex PCR pneumonia panel (PN-panel) in patients with pneumonia in the intensive care unit (ICU) had any effect on mortality or other important clinical outcomes. Methods: A retrospective cohort study was conducted on adult patients with pneumonia who required ICU admission in four institutions in Bogotá between November 2019 and June 2023. Mortality at 30 days, the length of the hospital and ICU stay, the duration of antibiotics, and their association with the PN-panel performance were evaluated using an inverse probability of the treatment weighting to adjust for covariates and potential confounders. Results: A total of 304 patients were included, including 150 with PN-panel, with a mean age of 65.0 years (SD 14.6). SARS-CoV-2 was the primary etiologic agent in 186 (61.2%) patients, and 256 (84.2%) patients had community-acquired pneumonia. No association was found between 30-day mortality and the PN-panel, with a HR of 1.14 (CI 95% 0.76–1.70), although the assessment by an infectious disease specialist was associated with a lower mortality HR of 0.29 (CI 95% 0.19–0.45). There was no association between the PN-panel and antimicrobial therapy duration or other clinical outcomes. Conclusions: The use of the PN-panel was not associated with changes in mortality, the duration of antibiotics, or hospital and ICU stays. To acquire greater rational decision-making, microbiological data produced by this test should be interpreted with aid of an antimicrobial stewardship program oriented by an infectious disease team that could take the clinical data and integrate the information provided.Keywords
Funding Information
- Universidad Nacional de Colombia (Hermes code 57576, QUIPÚ 202010040463)
This publication has 45 references indexed in Scilit:
- Diagnostic Stewardship in Community-Acquired Pneumonia With Syndromic Molecular TestingJAMA Network Open, 2024
- Point-of-care multiplex molecular diagnosis coupled with procalcitonin-guided algorithm for antibiotic stewardship in lower respiratory tract infection: a randomized controlled trialClinical Microbiology and Infection, 2023
- Multicentric evaluation of BioFire FilmArray Pneumonia Panel for rapid bacteriological documentation of pneumoniaClinical Microbiology and Infection, 2021
- Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysisClinical Microbiology and Infection, 2021
- Multinational evaluation of the BioFire® FilmArray® Pneumonia plus Panel as compared to standard of care testingEuropean Journal of Clinical Microbiology & Infectious Diseases, 2021
- The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United StatesChest, 2020
- Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic UseJAMA Network Open, 2020
- Burden of Community-Acquired Pneumonia and Unmet Clinical NeedsAdvances in Therapy, 2020
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studiesStatistics in Medicine, 2015
- Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unitClinical Therapeutics, 2010